RxDoctor Payments Data

Rosa Perez

Family · Eagle Pass, TXNPI 1255763918

Payments from drug & device makers

$1,881in general payments, 2019–2025

Across 93 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$333
  • Novo Nordisk$322
  • Boehringer Ingelheim$299
  • AstraZeneca$190
  • Abiomed$182
  • Amgen$107
  • plus $447 from 9 others

What the payments were for

  • Food & beverage$1,881100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,881 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$10,943
Medicare patients
37
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$115,460
FarxigaDapagliflozin Propanediol74$88,839
JardianceEmpagliflozin49$80,302
JanuviaSitagliptin Phosphate43$55,939
RybelsusSemaglutide22$29,814
LinzessLinaclotide33$25,839
TrulicityDulaglutide13$22,180
MounjaroTirzepatide20$21,937
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$15,952
EliquisApixaban11$14,037
Synjardy XrEmpagliflozin/Metformin Hcl21$12,526
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$12,484
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$6,630
VascepaIcosapent Ethyl11$4,708
Atorvastatin Calcium305$2,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$322$145,27479 claims
Boehringer IngelheimJardiance, Synjardy Xr$299$92,82770 claims
AstraZenecaFarxiga$190$88,83974 claims
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$333$44,42445 claims
AbbVieLinzess, Synthroid$96$26,77145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Eagle Pass

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →